http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2822004-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f2d3599fb8f8f479dba95ca9bb504884 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-9466 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-44 |
| filingDate | 2013-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ccdd389bc21e276fa507e825ce92fe95 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1fe64d8ab8ad585da2243737cd481bc4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_acfa2b3d131c1a9870bc59ecf8973c0a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eed8be6f8f2a8e413da850fac73833d3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a332fc6b1308ea2036897aa4fdf9f1e8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c301dfef02010e5851a80e019ac4c02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_912659e298ff56f23923f7aba1d41a95 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ed6679241716495b5bfe56fb0c8b8ff http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9dc773281471e16ea6ef9f4597c77ca |
| publicationDate | 2021-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2822004-T3 |
| titleOfInvention | Quetiapine Antibodies and Their Use |
| abstract | A composition comprising an isolated antibody, or a binding fragment thereof, which binds to quetiapine and which is an isolated antibody, or a binding fragment thereof comprising: a) a light chain CDR1 sequence which comprises amino acid residues 43 to 58 of SEQ ID NO: 19; a light chain CDR2 sequence comprising amino acid residues 74 to 80 of SEQ ID NO: 19; a light chain CDR3 sequence comprising amino acid residues 113 to 121 of SEQ ID NO: 19; a heavy chain CDR1 sequence comprising amino acid residues 45 to 54 of SEQ ID NO: 20; a heavy chain CDR2 sequence comprising amino acid residues 69 to 85 of SEQ ID NO: 20; and a heavy chain CDR3 sequence comprising amino acid residues 118 to 129 of SEQ ID NO: 20. b) a light chain CDR1 sequence comprising amino acid residues 43 to 58 of SEQ ID NO: 23; a light chain CDR2 sequence comprising amino acid residues 74 to 80 of SEQ ID NO: 23; a light chain CDR3 sequence comprising amino acid residues 113 to 121 of SEQ ID NO: 23; a heavy chain CDR1 sequence comprising amino acid residues 45 to 54 of SEQ ID NO: 24; a heavy chain CDR2 sequence comprising amino acid residues 69 to 85 of SEQ ID NO: 24; and a heavy chain CDR3 sequence comprising amino acid residues 123 to 129 of SEQ ID NO: 24; or c) a light chain CDR1 sequence comprising amino acid residues 43 to 58 of SEQ ID NO: 27; a light chain CDR2 sequence comprising amino acid residues 74 to 80 of SEQ ID NO: 27; a light chain CDR3 sequence comprising amino acid residues 113 to 121 of SEQ ID NO: 27; a heavy chain CDR1 sequence comprising amino acid residues 45 to 54 of SEQ ID NO: 28; a heavy chain CDR2 sequence comprising amino acid residues 69 to 85 of SEQ ID NO: 28; and a heavy chain CDR3 sequence comprising amino acid residues 123 to 129 of SEQ ID NO: 28. |
| priorityDate | 2012-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 118.